CJC-1295 with DAC + Ipamorelin

The CJC DAC + Ipamorelin combination represents a research formulation pairing two complementary growth hormone-axis peptides: CJC-1295 with Drug Affinity Complex (DAC) and Ipamorelin. CJC-1295 DAC is an extended-release GHRH analogue that binds covalently to circulating albumin through its lysine-biotin linker, dramatically extending its half-life to several days and providing sustained elevation of plasma GHRH-like activity. Ipamorelin, by contrast, is a selective GHS-R agonist that stimulates short, sharp pulses of GH release from the pituitary without significantly affecting cortisol or prolactin. Research into this combination has explored how the sustained baseline GHRH activity provided by CJC-1295 DAC may synergise with the acute GH pulses induced by Ipamorelin, potentially amplifying total GH output through engagement of two distinct pituitary receptor pathways. Studies have examined the downstream effects of this dual approach on IGF-1 levels, nitrogen retention, lean tissue accretion, and fat mobilisation. The combination has also been studied in the context of age-related somatopause research, where researchers investigate whether dual-pathway GH axis stimulation can more effectively restore aspects of youthful GH secretory patterns compared to single-agent approaches.